首页> 外文期刊>Phytomedicine : >Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells.
【24h】

Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells.

机译:Lobeline是一种来自Lobelia的哌啶生物碱,可以逆转肿瘤细胞中P-gp依赖性的多药耐药性。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Multidrug resistance (MDR) can limit efficacy of chemotherapy. The best studied mechanism involves P-gp (P-glycoprotein) mediated drug efflux. This study focuses on MDR reversal agents from medicinal plants, which can interfere with P-gp. Rhodamine 123 accumulation assay and flow cytometry analysis were employed to screen for P-gp dependant efflux inhibitors. Lobeline, a piperidine alkaloid from Lobelia inflata and several other Lobelia species, inhibited P-gp activity. MDR reversal potential of lobeline could be demonstrated in cells treated with doxorubicin in that lobeline can sensitize resistant tumor cells at non-toxic concentrations. However, lobeline cannot block BCRP (Breast Cancer Resistance Protein) dependent mitoxantrone efflux. Lobeline could be a good candidate for the development of new MDR reversal agents.
机译:多药耐药性(MDR)可能会限制化学疗法的疗效。研究最好的机制涉及P-gp(P-糖蛋白)介导的药物外排。这项研究的重点是药用植物的MDR逆转剂,它们可能会干扰P-gp。若丹明123积累测定和流式细胞仪分析被用来筛选依赖P-gp的外排抑制剂。 Lobeline,一种来自山梗菜和其他几种山梗菜的哌啶生物碱,可抑制P-gp活性。可以在用阿霉素处理的细胞中证明lobeline的MDR逆转潜力,因为lobeline可以以无毒浓度敏化耐药性肿瘤细胞。但是,肝胆碱不能阻断依赖BCRP(抗乳腺癌蛋白)的米托蒽醌外排。 Lobeline可能是开发新的MDR逆转代理的理想人选。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号